What a paper!Sought permission from the FDA to use REM-L,...

What a paper!
Sought permission from the FDA to use REM-L, permission granted and life saved. Mark-up that life saved to the FDA, which they will be aware of. OTAT clearance, then look out for a favourable BLA timescale for SRGvHD, as a game changer, big time.
Congratulations and a big thank you to @Moreforme and @Cadogan for bringing this news to the thread. Great news for that patient but bigger picture, the excitement was in the headline.
“Histological recovery of a rejecting intestinal graft after treatment with mesenchymal stem cells: continuing evidence of similarities with inflammatory bowel disease”
Not just 1 patient but yet another patient where inflammation was successfully treated. Another part of the body where inflammation responded. The article goes on to mention this and names SRGvHD, Lupus,
myocardial infarction and MS. Not just 1 patient but another contribution to the Data that shows the efficacy of this treatment for inflammation and again it is worth mentioning in collaboration with the FDA. No potency assay or MOA concerns for that patient. The company has spent millions and 12 months solving a problem which in the big picture was the easiest one to solve.OTAT will show that progress.
The most important one is it works and no side effects has already been established, the sheer breath of the opportunity, well that is ever expanding and this paper shows that.
We still have Perrin’s NEMJ paper to come!

Regards
Yelrom